How to Get Fosamax (Alendronate) in Massachusetts

What Is Alendronate and Why Massachusetts Prescribers Use It

Alendronate is the most widely prescribed oral bisphosphonate in the United States for postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced bone loss. It works by inhibiting osteoclast-mediated bone resorption, which measurably increases bone mineral density (BMD) and reduces fracture risk [1]. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), showed that alendronate reduced hip fracture risk by 47% and vertebral fracture risk by 55% over three years in women with low femoral neck BMD [2]. Those figures are the clinical benchmark against which newer agents are measured.

Massachusetts has an older-than-average population. According to the Massachusetts Executive Office of Elder Affairs, roughly 1.3 million residents are aged 65 or older, a cohort in which the National Osteoporosis Foundation estimates one in two women and one in four men will sustain an osteoporosis-related fracture [3]. Generic alendronate costs between $4 and $20 per month at most Massachusetts retail pharmacies, making it one of the most cost-accessible prescription options for bone health in the state [4].

The FDA approved alendronate sodium (Fosamax) for postmenopausal osteoporosis prevention and treatment, osteoporosis in men, and steroid-induced osteoporosis. The current FDA-approved label specifies 70 mg once weekly or 10 mg once daily for treatment, and 35 mg once weekly or 5 mg once daily for prevention [5]. Prescribers in Massachusetts follow these FDA-labeled doses; off-label dosing for Paget's disease of bone uses 40 mg once daily for six months [5].

Who Can Prescribe Fosamax in Massachusetts

Any licensed prescriber with an active Massachusetts controlled substance registration is authorized to write a prescription for alendronate, which is a non-controlled Schedule prescription drug. That includes MDs, DOs, NPs with full independent practice authority, PAs with a supervising physician agreement, and certified nurse-midwives (CNMs) within their scope [6].

Massachusetts granted nurse practitioners full practice authority under M.G.L. c. 112, § 80E effective 2021, removing the requirement for a supervising physician to co-sign NP prescriptions for most medications including bisphosphonates. A PA in Massachusetts may prescribe alendronate provided the written collaboration agreement with the supervising physician does not restrict it, which is rare [6].

Endocrinologists, rheumatologists, and primary care physicians each manage osteoporosis patients in Massachusetts. The American Association of Clinical Endocrinologists (AACE) 2020 Clinical Practice Guidelines recommend alendronate as a first-line agent for patients at high fracture risk with no contraindications to oral bisphosphonate therapy [7]. The Endocrine Society's 2019 guidelines on pharmacological management of osteoporosis similarly list alendronate alongside risedronate and zoledronic acid as preferred initial agents [8].

Telehealth Prescribing of Fosamax in Massachusetts

Massachusetts allows telehealth-based prescribing of alendronate without a prior in-person visit, provided the prescriber holds an active Massachusetts license and meets the standard of care for evaluation. The Massachusetts Board of Registration in Medicine has maintained telehealth prescribing guidance that permits synchronous audio-video visits to satisfy the patient-prescriber relationship requirement for non-controlled medications [9].

Telehealth works well for alendronate because the drug is oral, weekly, and does not require in-office administration. The prescriber must still review imaging and labs remotely. Most telehealth platforms operating in Massachusetts require patients to upload a recent DEXA scan result (within two years) and current lab values before or at the time of the video visit. If labs are missing, the provider will order them electronically and delay the prescription until results return, typically two to five business days.

Several national telehealth companies hold Massachusetts prescriber licenses and offer osteoporosis consultations. Patients should confirm the platform's prescribers are licensed in Massachusetts (license lookup: Massachusetts Board of Registration in Medicine) and that the platform transmits prescriptions directly to a Massachusetts-licensed pharmacy. Alendronate is not a controlled substance, so telehealth prescribers face no DEA-specific telemedicine barriers for this drug.

Required Labs and Imaging Before Prescribing

Before writing a first prescription for alendronate, Massachusetts prescribers follow the workup outlined in the AACE and Endocrine Society guidelines. Baseline evaluation includes [7, 8]:

• DEXA scan of the lumbar spine and hip to establish a T-score. A T-score of -2.5 or lower at any site confirms osteoporosis; a T-score between -1.0 and -2.5 with high 10-year FRAX fracture probability confirms high-risk osteopenia [10].
• Serum calcium to rule out hypocalcemia, an absolute contraindication to bisphosphonate initiation.
• Serum creatinine and estimated GFR (eGFR) because alendronate is contraindicated when eGFR falls below 35 mL/min/1.73 m² [5].
• 25-hydroxyvitamin D to identify deficiency. The Endocrine Society defines vitamin D deficiency as a level below 20 ng/mL [11]. Alendronate should be initiated only after vitamin D has been repleted or concurrent repletion is planned, since uncorrected deficiency can exacerbate hypocalcemia.
• Thyroid-stimulating hormone (TSH) in postmenopausal women to exclude thyroid dysfunction as a secondary cause of bone loss [8].
• Complete metabolic panel (CMP) to identify hepatic or renal conditions that affect drug metabolism.

Telehealth prescribers typically accept labs drawn within the past 90 days. For DEXA scans, most accept results within 24 months, consistent with Medicare monitoring intervals [12]. Patients who have never had a DEXA scan can arrange one through a Massachusetts radiology center or hospital outpatient department; DEXA scans typically cost $75, $250 without insurance, and Medicare Part B covers one DEXA every 24 months for eligible beneficiaries [12].

HealthRX Pre-Alendronate Lab Checklist for Massachusetts Telehealth Visits

| Test | Threshold That Delays Rx | Action Before Starting | |---|---|---| | Serum calcium | <8.5 mg/dL | Replicate, correct deficiency first | | eGFR | <35 mL/min/1.73 m² | Switch to IV bisphosphonate or alternative | | 25-OH vitamin D | <20 ng/mL | Load vitamin D3; recheck in 8 weeks | | T-score (DEXA) | Better than -1.0 without risk factors | Lifestyle counseling; Rx not indicated | | Creatinine trend | Rising over 3 months | Nephrology referral before Rx |

This framework consolidates the AACE 2020 and Endocrine Society 2019 screening criteria into a single pre-visit checklist that Massachusetts telehealth platforms may use during chart review.

How to Fill a Fosamax Prescription at a Massachusetts Pharmacy

Generic alendronate 70 mg tablets are stocked at virtually every retail pharmacy chain operating in Massachusetts, including CVS, Walgreens, Rite Aid, and independent pharmacies. The drug is listed on most Tier 1 or Tier 2 formulary positions for commercial plans. Without insurance, GoodRx and similar discount programs bring the cost of a four-tablet supply (one month) to between $4 and $12 at Massachusetts pharmacies [4].

Electronic prescriptions (eRx) for alendronate are transmitted directly from the telehealth platform or prescriber's EHR to the patient's chosen pharmacy. Because alendronate is not a controlled substance, no paper prescription or DEA compliance hold applies. Most Massachusetts pharmacies fill non-controlled electronic prescriptions within two to four hours of receipt during business hours. Same-day pickup is standard.

Mail-order options include CVS Caremark, Express Scripts, and OptumRx, each of which ships to Massachusetts addresses. A 90-day supply by mail typically runs $10, $30 for generic alendronate under commercial insurance, and patients report delivery within three to five business days of prescription processing.

503A Compounding Pharmacies. Some Massachusetts residents require alternative formulations. Licensed 503A compounding pharmacies in Massachusetts may prepare alendronate in liquid suspension for patients with swallowing difficulties or esophageal conditions that preclude the standard tablet. The Massachusetts Board of Pharmacy licenses and inspects 503A facilities; patients should verify a compounding pharmacy's active license on the Massachusetts Board of Pharmacy license search before ordering. Compounded alendronate is not FDA-approved as a finished dosage form and carries a different risk profile than the commercially manufactured tablet [5].

MassHealth (Medicaid) Coverage and Prior Authorization

MassHealth, Massachusetts's Medicaid program, covers generic alendronate and branded Fosamax for osteoporosis, but requires prior authorization (PA) for most enrollees. The PA criteria align with the National Committee for Quality Assurance (NCQA) Osteoporosis Management in Women measure: documentation of a bone density test or fragility fracture, and failure of or contraindication to non-pharmacological management [13].

To submit a PA request for a MassHealth enrollee in Massachusetts, the prescribing clinician or their staff must provide:

1. The DEXA T-score or documentation of a low-trauma fracture.
2. A confirmed diagnosis code (ICD-10 M81.0 for postmenopausal osteoporosis without fracture, or M80.xx for osteoporosis with fracture).
3. Documentation that vitamin D and calcium supplementation have been recommended.
4. The prescriber's NPI number and Massachusetts license number.

MassHealth processes standard PA requests within 14 calendar days and expedited requests within 72 hours when the prescriber documents clinical urgency [13]. Commercial insurers in Massachusetts generally process alendronate PAs within three to seven business days. Some plans apply step therapy requiring a 90-day trial of calcium and vitamin D supplementation before approving alendronate, though patients with T-scores at or below -2.5 or a documented fragility fracture typically bypass step therapy under most MA plan contracts.

Transferring an Existing Fosamax Prescription to Massachusetts

Patients relocating to Massachusetts who already take alendronate have two transfer pathways. First, a retail pharmacy chain can transfer a remaining refill count from an out-of-state pharmacy to a Massachusetts location, provided the original state's regulations allow transfer and the prescription has refills remaining. Under Massachusetts pharmacy law (247 CMR 9.00), a pharmacist may transfer a valid out-of-state prescription for a non-controlled substance once, or multiple times if the originating state permits [14].

Second, and more reliably, the patient schedules a new prescriber visit in Massachusetts (in-person or telehealth) and establishes care before the out-of-state supply runs out. Because alendronate dosing is once weekly, most patients have a comfortable two- to four-week supply to bridge while arranging a new prescription. A telehealth visit with a Massachusetts-licensed provider can often be scheduled within 48 to 72 hours.

Out-of-state prescriptions written by prescribers not licensed in Massachusetts cannot be filled at Massachusetts pharmacies for more than a 30-day emergency supply under M.G.L. c. 112, § 42D [14]. Patients should not rely on an out-of-state prescriber to continue refilling once Massachusetts residency is established.

Monitoring After Starting Alendronate

The AACE 2020 guidelines recommend repeating DEXA scans every one to two years after alendronate initiation to assess response [7]. A meaningful BMD response is defined as no significant loss (within the least significant change of the DEXA machine, typically 2 to 4%) or a measurable gain. Patients who lose bone density despite adherence warrant evaluation for secondary causes of osteoporosis, reassessment of vitamin D status, and possible switch to anabolic therapy such as teriparatide or romosozumab [8].

Serum calcium and creatinine should be rechecked approximately three months after starting alendronate, particularly in patients with baseline creatinine near the threshold. The Endocrine Society's 2019 guidelines specify that renal function should be monitored annually in patients on long-term bisphosphonate therapy [8].

Alendronate carries a boxed warning for esophageal reactions. The FDA label instructs patients to take the tablet with 6, 8 ounces of plain water, remain upright for at least 30 minutes after ingestion, and take the dose at least 30 minutes before any food, beverage, or other medication [5]. Non-adherence to these instructions is the leading cause of upper GI adverse events. A Massachusetts prescriber or pharmacist should counsel on this protocol at every new prescription, consistent with the FDA's medication guide requirement for alendronate [5].

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) are rare but recognized adverse effects with long-term bisphosphonate use. The American Society for Bone and Mineral Research task force reports ONJ incidence at 1 in 10,000 to 1 in 100,000 patient-years with oral bisphosphonates [15], and AFF risk increases after five or more years of continuous use [16]. Most Massachusetts prescribers reassess the need for continued therapy at five years, offering a drug holiday to lower-risk patients based on T-score trajectory and FRAX score at that point [7].

Duration, Drug Holidays, and Switching Agents

The standard treatment duration for alendronate in postmenopausal osteoporosis is three to five years for initial therapy, followed by a structured reassessment. The FLEX trial (N=1,099) examined outcomes after five years of alendronate and found that continuing for an additional five years reduced clinical vertebral fracture risk by 55% compared with placebo in women with a femoral neck T-score at or below -2.5 at year five [17]. Women with T-scores above -2.5 after five years may discontinue and enter a monitoring period, sometimes called a drug holiday.

Drug holidays typically last two to three years, during which BMD is monitored annually. If T-score drops meaningfully or a fracture occurs, alendronate or an alternative bisphosphonate is restarted [7]. Patients switching from alendronate to denosumab (Prolia) require particular vigilance because abrupt discontinuation of denosumab without a bisphosphonate bridge causes rapid, rebound bone loss; the AACE guidelines specify that a bisphosphonate should be prescribed within six months of the last denosumab dose [7].

For patients who cannot tolerate weekly oral alendronate due to GI side effects, Massachusetts prescribers may switch to intravenous zoledronic acid (Reclast) 5 mg once yearly, or oral risedronate 35 mg weekly, or subcutaneous denosumab 60 mg every six months. Each of these requires a separate insurance authorization process in Massachusetts.

Vitamin D and Calcium Co-Prescribing

Alendronate will not produce optimal results without adequate calcium and vitamin D. The National Academy of Medicine recommends 1,000, 1 to 200 mg of dietary calcium daily for adults aged 51 and older, with supplementation to fill the gap if diet falls short [18]. The Endocrine Society recommends maintaining serum 25-OH vitamin D at 30 ng/mL or higher in patients being treated for osteoporosis [11]. A typical Massachusetts prescriber will co-prescribe vitamin D3 600, 2 to 000 IU daily and recommend dietary calcium from dairy, fortified foods, or leafy greens [11, 18].

Over-supplementation with calcium carries cardiovascular risk. A 2011 BMJ meta-analysis (N=12,000 across 11 trials) found that calcium supplement use without co-administered vitamin D was associated with a 27% higher risk of myocardial infarction [19]. The clinical consensus in Massachusetts primary care and endocrinology is to prioritize dietary calcium over supplements wherever possible, and to limit supplement doses to 500 mg elemental calcium per dose for optimal absorption [7, 18].